Results 1 to 10 of about 86,443 (111)
In silico prediction of mutant HIV-1 proteases cleaving a target sequence. [PDF]
PLoS ONE, 2014 HIV-1 protease represents an appealing system for directed enzyme re-design, since it has various different endogenous targets, a relatively simple structure and it is well studied. Recently Chaudhury and Gray (Structure (2009) 17: 1636-1648) published a
Jan H Jensen +3 more
doaj +10 more sources
Molecular Basis for Drug Resistance in HIV-1 Protease
Viruses, 2010 HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer +12 more
doaj +3 more sources
Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication. [PDF]
PLoS ONE, 2008 Acute HIV-1 infection of CD4 T cells often results in apoptotic death of infected cells, yet it is unclear what evolutionary advantage this offers to HIV-1.
Gary D Bren +6 more
doaj +1 more source
Biomolecules, 2021 Understanding the underlying molecular interaction during a therapy switch from lopinavir (LPV) to darunavir (DRV) is essential to achieve long-term virological suppression.
Simeon Eche +3 more
doaj +1 more source
Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors
Molecules, 2023 The use of protease inhibitors in human immunodeficiency virus type 1 (HIV-1) treatment is limited by adverse effects, including metabolic complications. To address these challenges, efforts are underway in the pursuit of more potent and less toxic HIV-1
Sunday N. Okafor +7 more
doaj +1 more source
Predicting HIV-1 Protease Cleavage Sites With Positive-Unlabeled Learning
Frontiers in Genetics, 2021 Understanding the substrate specificity of HIV-1 protease plays an essential role in the prevention of HIV infection. A variety of computational models have thus been developed to predict substrate sites that are cleaved by HIV-1 protease, but most of ...
Zhenfeng Li +3 more
doaj +1 more source
Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease
Biology, 2012 Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari +6 more
doaj +1 more source
Universitas Scientiarum, 2019 The HIV-1 protease plays an essential role in the replication cycle of HIV-1; therefore there is a direct need to develop novel inhibitors of the HIV-1 protease, which can cease the viral replication.
Ammara Akhtar, Waqar Hussain, Nouman Rasool3
doaj +1 more source
Mangiferin, an Anti-HIV-1 Agent Targeting Protease and Effective against Resistant Strains
Molecules, 2011 The anti-HIV-1 activity of mangiferin was evaluated. Mangiferin can inhibit HIV-1ⅢB induced syncytium formation at non-cytotoxic concentrations, with a 50% effective concentration (EC50) at 16.90 μM and a therapeutic index (TI) above 140. Mangiferin also
Rui-Rui Wang +6 more
doaj +1 more source
PLoS ONE, 2021 Determining the unbinding pathways of potential small molecule compounds from their target proteins is of great significance for designing efficacious treatment solutions.
Farzin Sohraby, Hassan Aryapour
doaj +1 more source